NCT04968366 — Beijing Tiantan Hospital cancer vaccine trial
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
Registry record
| Registry ID | NCT04968366 ↗ |
|---|---|
| Lead sponsor | Beijing Tiantan Hospital |
| Collaborators | ZhongSheng BioTech Inc. |
| Phase | Phase 1 |
| Status | Completed |
| Indication | Glioblastoma Multiforme of Brain |
| Enrollment | 11 participants |
| Start date | 2021-07-30 |
| Primary completion | 2024-04-30 |
| Last registry update | 4 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04968366), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04968366?
NCT04968366 (Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery) is registered on ClinicalTrials.gov as Phase 1, sponsored by Beijing Tiantan Hospital.
Is NCT04968366 recruiting?
As of the 2026-05-04 registry update, NCT04968366 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04968366?
The lead sponsor is Beijing Tiantan Hospital. Collaborators: ZhongSheng BioTech Inc..
What condition does NCT04968366 study?
The registered condition is Glioblastoma Multiforme of Brain. Primary completion is listed as 2024-04-30.
Are results available for NCT04968366?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04968366.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.